PURPOSE: To describe the use of fluocinolone acetonide implants (Retisert) in Vogt-Koyanagi-Harada disease (VKH). DESIGN: Interventional case series. METHODS: Retrospective review of medical records. RESULTS: Two patients with VKH requiring high-dose systemic corticosteroid therapy to control their inflammation and bilateral serous retinal detachments received bilateral fluocinolone acetonide implants. Upon tapering of systemic corticosteroids, one patient had recurrent serous retinal detachments and the other patient's anterior chamber and vitreous inflammation returned. CONCLUSIONS: The authors' experience with fluocinolone acetonide implants in VKH has been mixed with an inability to fully taper off of systemic corticosteroids.
PURPOSE: To describe the use of fluocinolone acetonide implants (Retisert) in Vogt-Koyanagi-Harada disease (VKH). DESIGN: Interventional case series. METHODS: Retrospective review of medical records. RESULTS: Two patients with VKH requiring high-dose systemic corticosteroid therapy to control their inflammation and bilateral serous retinal detachments received bilateral fluocinolone acetonide implants. Upon tapering of systemic corticosteroids, one patient had recurrent serous retinal detachments and the other patient's anterior chamber and vitreous inflammation returned. CONCLUSIONS: The authors' experience with fluocinolone acetonide implants in VKH has been mixed with an inability to fully taper off of systemic corticosteroids.
Authors: Carl P Herbort; Ahmed M Abu El Asrar; Joyce H Yamamoto; Carlos E Pavésio; Vishali Gupta; Moncef Khairallah; Ilknur Tugal-Tutkun; Masoud Soheilian; Masuru Takeuchi; Marina Papadia Journal: Int Ophthalmol Date: 2016-11-14 Impact factor: 2.031